E Cigarette UseNCT07422415
Effects of E-Cigarette Use Among Young Egyptian Adults
An observational study of E Cigarette Use, run by Mansoura University Hospital at 1 site in Egypt.
Trial summary
Electronic cigarettes (E-cigarettes) have gained significant popularity as an alternative to traditional combustible tobacco cigarette smoking. E-cigarettes are marketed as a safer alternative to conventional smoking forms. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- E Cigarette Use
- What is being tested?
- Pulmonary Function test
- How many people
- 104 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2025to 1 Feb 2026
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: A total of 104 participants were enrolled and allocated into two equal groups: Group I: Exclusive e-cigarette users (n = 52) and Group II: Non-smoker controls (n = 52).
Who may be able to join
- Age > 18 years
- E-cigarette users (≥6 months of regular use)
- No prior history of chronic pulmonary disease
Who cannot join
- Dual users (both e-cigarettes and traditional tobacco)
- History of chronic respiratory illnesses (e.g., asthma, COPD)
- immunocompromised
- Systemic chronic diseases
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Respiratory, Functional, and Radiological Effects of E-Cigarette Use Among Young 1 Egyptian Adults: A Cross-Sectional Study
Electronic cigarettes (E-cigarettes) have gained significant popularity as an alternative to traditional combustible tobacco cigarette smoking. E-cigarettes are marketed as a safer alternative to conventional smoking forms. Many chronic smokers suppose that e-cigarettes are risk-free and can be used effectively as a smoking cessation tool. The market size of e-cigarette is increasing because of its rising popularity among the youth even though it is not an approved Food and Drug Administration (FDA) product yet
Read the detailed description
Most daily life activities as walking and household chores that affect quality of life are performed at a submaximal level of exertion. E-cigarettes may affect overall physical fitness and cardiovascular health. It is important to evaluate responses of all body systems interacting during exercise, including cardiovascular and pulmonary function, systemic circulation, peripheral circulation, blood, neuromuscular units, muscle metabolism, oxygen transport and utilization within skeletal muscles. The knowledge gap regarding the potential negative health effects of E-cigarettes is crucial, as e-cigarettes are newly prevailing smoking tools that are gaining rising popularity among the youth. Additionally, the false perception of the unregulated electronic cigarette smoking as a safe recreational habit may increase the prevalence among the population. The aim of this work is to assess the clinical and functional impact of E-cigarettes garette use in young Egyptian adults, and to evaluate the role of chest CT in follow-up of identified abnormalities.
- Conditions
- E Cigarette Use
- Being tested
- Pulmonary Function test
- Keywords
- E-cigarettes, Vaping
- Medical subject headings
- Vaping
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pulmonary Function testDiagnostic test
Spirometry was performed measure forced expiratiory volume at 1st second (FEV₁), forced vital capacity (FVC), and FEV₁/FVC ratio.
| Study group | Role | What they receive |
|---|---|---|
| Non-smoker controls | Patients were included with Age ≥ 18 years, Non smokers Receives: Diagnostic Test: Pulmonary Function test | |
| Exclusive e-cigarette users | Patients were included if Age ≥ 18 years, Exclusive e-cigarette users (Participants were considered exclusive e-cigarette users if they had used e-cigarettes regularly for ≥ 6 months). Receives: Diagnostic Test: Pulmonary Function test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Spirometer parameters assessment
Spirometry was performed to measure forced expiratory volume at 1st second (FEV₁)
Measured: 3 months
Spirometer assessment
Spirometry was performed to measure FEV₁/FVC ratio
Measured: 3 months
Spirometer
Spirometry was performed to measure forced vital capacity (FVC)
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2026
- Study start1 Sep 2025
- Primary completion31 Dec 2025
- Study completion1 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for E Cigarette UseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 104 participants (actual)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- Mansoura University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Abd Elmoniem Mohamed, Mansoura University Hospital
- Investigators
- Mohamed AbdElmoniem, Principal investigator, Lecturer of chest medicine faculty of medicine Mansoura university
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07422415
- Sponsor's protocol ID
- R.25.09.3347
- Status last verified
- Feb 2026
- First submitted
- 12 Feb 2026
- Last updated
- 20 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Respiratory, Functional, and Radiological Effects of E-Cigarette Use Among Young 1 Egyptian Adults: A Cross-Sectional Study
- ClinicalTrials.gov ID
- NCT07422415
- Acronym / sponsor ID
- R.25.09.3347
- Conditions
- E Cigarette Use
- Keywords
- E-cigarettes, Vaping
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 104 participants (actual)
- Lead sponsor
- Mansoura University HospitalUniversity, hospital or other
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 1 Feb 2026 (actual)
- First posted
- 20 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Electronic cigarettes (E-cigarettes) have gained significant popularity as an alternative to traditional combustible tobacco cigarette smoking. E-cigarettes are marketed as a safer alternative to conventional smoking forms. Many chronic smokers suppose that e-cigarettes are risk-free and can be used effectively as a smoking cessation tool. The market size of e-cigarette is increasing because of its rising popularity among the youth even though it is not an approved Food and Drug Administration (FDA) product yet
Detailed description
Most daily life activities as walking and household chores that affect quality of life are performed at a submaximal level of exertion. E-cigarettes may affect overall physical fitness and cardiovascular health. It is important to evaluate responses of all body systems interacting during exercise, including cardiovascular and pulmonary function, systemic circulation, peripheral circulation, blood, neuromuscular units, muscle metabolism, oxygen transport and utilization within skeletal muscles. The knowledge gap regarding the potential negative health effects of E-cigarettes is crucial, as e-cigarettes are newly prevailing smoking tools that are gaining rising popularity among the youth. Additionally, the false perception of the unregulated electronic cigarette smoking as a safe recreational habit may increase the prevalence among the population. The aim of this work is to assess the clinical and functional impact of E-cigarettes garette use in young Egyptian adults, and to evaluate the role of chest CT in follow-up of identified abnormalities.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Month
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Non-smoker controls | – | Diagnostic Test: Pulmonary Function testPatients were included with Age ≥ 18 years, Non smokers |
| Exclusive e-cigarette users | – | Diagnostic Test: Pulmonary Function testPatients were included if Age ≥ 18 years, Exclusive e-cigarette users (Participants were considered exclusive e-cigarette users if they had used e-cigarettes regularly for ≥ 6 months). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- A total of 104 participants were enrolled and allocated into two equal groups: Group I: Exclusive e-cigarette users (n = 52) and Group II: Non-smoker controls (n = 52).
Key inclusion criteria (3 listed)
- Age > 18 years
- E-cigarette users (≥6 months of regular use)
- No prior history of chronic pulmonary disease
Key exclusion criteria (4 listed)
- Dual users (both e-cigarettes and traditional tobacco)
- History of chronic respiratory illnesses (e.g., asthma, COPD)
- immunocompromised
- Systemic chronic diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pulmonary Function testSpirometry was performed measure forced expiratiory volume at 1st second (FEV₁), forced vital capacity (FVC), and FEV₁/FVC ratio. | Diagnostic test | Exclusive e-cigarette users, Non-smoker controls |
Primary outcome
Spirometer parameters assessment
Time frame: 3 months
Spirometry was performed to measure forced expiratory volume at 1st second (FEV₁)
Spirometer assessment
Time frame: 3 months
Spirometry was performed to measure FEV₁/FVC ratio
Spirometer
Time frame: 3 months
Spirometry was performed to measure forced vital capacity (FVC)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2026.
Related trials for E Cigarette Use
Not yet recruitingPhase 1
PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis
Cigarette Smoking-Related Carcinoma
Active, not recruiting
Vaping Cessation Using the Ottawa Model for Smoking Cessation Among E-Cigarette Users
Tobacco Smoking, Vaping
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco
Active, not recruiting
Mindful Breaths: Mindfulness for Young Adult Vaping
Vaping Cessation
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohamed AbdElmoniem principal investigator
Lecturer of chest medicine faculty of medicine Mansoura university
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of E Cigarette Use, run by Mansoura University Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Spirometer parameters assessment (time frame: 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2026.